Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Beware The 'Pitchforks,' Pharma

This article was originally published in Scrip

Executive Summary

While lawmakers on March 17 spent another day on Capitol Hill beating up on Turing Pharmaceuticals Inc., it was the model that company and other firms like Retrophin Inc. and Valeant Pharmaceuticals International Inc. base their businesses on – buying up sole-source medicines and significantly raising their prices, rather than engaging in research and development activities – that was under scrutiny at the Senate Special Committee on Aging.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts